Abstract
Objective. To evaluate the clinical efficacy and safety of a herbal drug combination manufactured by Alfit Plus compony (Fitol-1 Mastoprof capsules + Mastokrel cream gel) as monotherapy in reproductive-aged patients with ultrasound signs of benign breast dysplasia and mastalgia. Materials and Methods. A single-center, open, prospective, pre-post comparative study was conducted. The study included 30 patients aged 21 to 45 years with mastalgia (VAS intensity >40 mm) and ultrasound signs of benign breast dysplasia corresponding to BIRADS category 2. Exclusion criteria were BIRADS ≥3, the use of hormonal medications, and severe somatic pathology. At baseline and after 3 months, the following parameters were evaluated: complaints, pain intensity using VAS, breast ultrasound data (on days 7–9 of the menstrual cycle), anthropometric measurements, blood pressure, and heart rate. Patients received Fitol-1 Mastoprof (1 capsule twice daily, per os) and Mastokrel cream gel (applied to the breasts morning and evening) for 3 months. Statistical analysis was performed using paired Student's t-test and χ² test (significance set at p<0.05). Results. The mean age was 37.0 ± 7.29 years; normal menstrual cycle was present in 70.0% of the cases. The baseline intensity of mastalgia according to VAS was – 53,5 ± 15,258 mm. Ultrasound revealed diffuse changes in all patients, small cysts (3–7 mm) in 60.0%, and duct ectasia in 15.0%. After 3 months of therapy, mastalgia persisted in only 6 patients (20.0%) with a reduction in intensity to 16, 66 ± 3, 47 mm (p <0.001); the mean VAS score for the entire group was 3.3 ± 0.42 mm. Galactorrhea was not observed in any patient. Ultrasound findings improved in 76.6% of cases (p <0.001): cysts regressed in 12 of 18 patients, and duct ectasia persisted in only 1 of 15 patients. No adverse events were reported and all patients noted the convenience of the treatment regimen. Conclusion. Three-month monotherapy with the combination of Fitol-1 Mastoprof (capsules) and Mastokrel cream gel in reproductive-aged patients with benign breast dysplasia allows complete resolution or significant reduction of mastalgia in 80% of cases, improves ultrasound findings in 76.6% and is not associated with adverse events. The results obtained support the use of this combination patients with mastalgia and benign breast dysplasia.